+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review

Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Nektar Therapeutics (Nektar) discovers and develops novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company’s technology platforms offer a wide range of functional attributes, which optimizes and enhances the profile of a wide range of molecules including large classes of drugs targeting numerous disease areas. The company’s products focus on various disease areas including cancer, pain, infections, and immunology among others. Its research and development involve peptides, proteins, antibodies, small molecule drugs, and other potential biological drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

Nektar Therapeutics Key Recent Developments

  • Apr 17, 2023: Nektar Therapeutics announces strategic reprioritization and cost restructuring plan
  • Feb 28, 2023: Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
  • Nov 03, 2022: Nektar Therapeutics Reports Third Quarter 2022 Financial Results
  • Aug 04, 2022: Nektar Therapeutics Reports Second Quarter 2022 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Nektar Therapeutics - Key Facts
  • Nektar Therapeutics - Key Employees
  • Nektar Therapeutics - Key Employee Biographies
  • Nektar Therapeutics - Major Products and Services
  • Nektar Therapeutics - History
  • Nektar Therapeutics - Company Statement
  • Nektar Therapeutics - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Nektar Therapeutics - Business Description
  • Other Break-up: License, Collaboration and Other Revenue
  • Performance
  • Other Break-up: Non-cash Royalty Revenue Related to Sale of Future Royalties
  • Performance
  • Other Break-up: Product Sales
  • Performance
  • Geographical Segment: Rest of World
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Nektar Therapeutics - Corporate Strategy
  • Nektar Therapeutics - SWOT Analysis
  • SWOT Analysis - Overview
  • Nektar Therapeutics - Strengths
  • Nektar Therapeutics - Weaknesses
  • Nektar Therapeutics - Opportunities
  • Nektar Therapeutics - Threats
  • Nektar Therapeutics - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Nektar Therapeutics, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 17, 2023: Nektar Therapeutics announces strategic reprioritization and cost restructuring plan
  • Feb 28, 2023: Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
  • Nov 03, 2022: Nektar Therapeutics Reports Third Quarter 2022 Financial Results
  • Aug 04, 2022: Nektar Therapeutics Reports Second Quarter 2022 Financial Results
  • Jul 01, 2022: Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer
  • May 05, 2022: Nektar Therapeutics Reports First Quarter 2022 Financial Results
  • Apr 25, 2022: Nektar Therapeutics announces strategic reorganization plan and corporate outlook
  • Feb 28, 2022: Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results
  • Jan 05, 2022: Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Nektar Therapeutics, Key Facts
  • Nektar Therapeutics, Key Employees
  • Nektar Therapeutics, Key Employee Biographies
  • Nektar Therapeutics, Major Products and Services
  • Nektar Therapeutics, History
  • Nektar Therapeutics, Other Locations
  • Nektar Therapeutics, Subsidiaries
  • Nektar Therapeutics, Key Competitors
  • Nektar Therapeutics, Ratios based on current share price
  • Nektar Therapeutics, Annual Ratios
  • Nektar Therapeutics, Interim Ratios
  • Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Nektar Therapeutics, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Nektar Therapeutics, Performance Chart (2018 - 2022)
  • Nektar Therapeutics, Ratio Charts
  • Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Mountain View Pharmaceuticals Inc
  • Ascendis Pharma AS
  • Novo Nordisk AS
  • Biogen Inc
  • Juno Therapeutics Inc
  • Celgene Corp
  • Mountain View Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Ltd
  • MacroGenics Inc
  • Novo Nordisk AS
  • Biogen Inc
  • NOF Corp
  • NOF Corp
  • MacroGenics Inc
  • Dr. Reddy's Laboratories Ltd
  • Celgene Corp